Christian Fernandez Olortegui

Radiation Oncologist at Cook County Hospital | Head & Neck, Gyn, GU

[Christian Fernandez Olortegui @ChrisFernOlor]

Amazing video beautifully demonstrating #radiationoncology by @TargetingCancer shared at @roecsg 2019 symposium #roecsg #radonc #target
https://t.co/mj3PFyK2dD

[Tyler Seibert - tmp account. Go follow @TylerSbrt @TylerSbrt7]

🚨The sequel is here!! The other 👞 drops.

Cribriform morphology in ProtecT — now in prostatectomy specimens

#ProstateCancer #radonc #UroSoMe

@UroToday @APCCC_Lugano @PCF_Science @OncoAlert

🧵1️⃣

[noah kulwin @nkulw]

Footage of ICE kidnapping PRE-K TEACHERS in Chicago that my sister sent to me. Rayito de Sol on Addison

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

Financial Principles for Radiation Oncologists Bootcamp

Part 1: How to Plan Your Financial Future

With @A_CT_SimMDJD

Collaboration w @RadiumSociety @ASTRO_org @ACRORadOnc @ARRO_org @TrudyWuMD @MaryMahoney02 #radonc

Parts 2-3 coming soon

https://t.co/do1rv4D2Nq

[Gustavo @gusviani]

SBRT vs. Ablation for Kidney Cancer: A Game-Changer? @OncoAlert 🚀🔥 #RadOnc
🧵 Ablative therapies for localized renal cell carcinoma (RCC): What’s the best approach?
📢 A new Lancet Oncology study compares SBRT, radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation. How do these stack up? Let’s break it down. 👇
https://t.co/B9WsryJZVG

[Gustavo @gusviani]

🚨 The 2024 FROGG Guidelines for Post-Prostatectomy Radiation Therapy (PPRT) are here, bringing groundbreaking updates backed the by the latest evidence❗️@OncoAlert 🧵1/7

[Gustavo @gusviani]

Do all early-stage breast cancer patients need axillary surgery? The INSEMA trial challenges this long-standing practice, showing that skipping sentinel lymph node biopsy (SLNB) may be safe for select patients. ☢️ plays a key role. Let’s dive into the data. 🧵 1/13#RadOnc #BreastSurgery”

[Dr. Nina Niu Sanford @NiuSanford]

RACE-GB is out! Congrats to authors for FIRST RCT of RT in gallbladder cancer.

N=135 w unresectable GBC, after 4c chemo, addition of RT (vs. obs) improved OS from 4 to 10 months.

Several limitations (single center, chemo gem/cis & 4 mo) but OS benefit shouldn’t be ignored.

[Gautier Marcq @gautiermarcq]

Just in 👉 @JCO_ASCO Benefit of Whole-Pelvis Radiation ☢️ for Patients With #MIBC
https://t.co/uY8XqgrCF8

👇👇👇TWEETORIAL 👇👇👇

[Corinne Faivre-Finn @finn_corinne]

Consensus guidelines on the diagnosis and management of RT pneumonitis
▶️ Delphi consensus
▶️Practical guide to assess risk in individual patients
▶️unmet need-> clarify the relationship between RT-drug-induced pneumonitis + optimal management strategies
https://t.co/PXFmMuLLjl

[medmalreviewer @medmalreviewer]

Really incredible article about an insurance company disciplining a doctor for following the standard of care.

https://t.co/eCNceE5xIc

Looks like their “experts” are just as bad as some of the most crooked plaintiff experts I see.

[David Sher @DavidSherMD]

Thrilled to see that KEYNOTE-0412 has been published in Lancet Oncology.

TL/DR: The utility of an CRT/IO combination hasn’t been figured out yet, but the field is getting much closer.

https://t.co/UWlZPSHowU

[Zed Zha, MD, FAAFP @DrZedZha]

MONTHs ago, I saw a young patient who lost all her hair one day. And as someone who developed alopecia areata ophiasis and lost all her eyebrows and hairlines, I KNOW I needed to act fast.

So far, this is the despicable game we have been asked to play with coordinated care:

- I tried “traditional” therapies with steroids, injections, etc. Failed (of course).
- I prescribed a Biologics that’s FDA approved for alopecia areata for patients over 12, and documented (heartbreaking) photos, and detailed reasoning why we needed the medication
- Insurance denied it. (#1)
- I appealed, got denial #2.
- I requested peer to peer discussion and blocked my busy clinic time to do it.
- A non-physician called my nursing staff and REFUSED to talk to me and denied my demand to talk to a peer, so even my peer to peer was denied! (#3)
- Told us we needed an exception application. I put together a 38 page letter including the FDA approval and clinical trials and my notes, again.
- We didn’t hear back for weeks.
- Then we got denial #4 because we “didn’t file the right appeal.”
- I filed yet ANOTHER appeal.
- We’ve not heard back again for weeks now. We keep calling and be put on hold for 30 minutes at a time.

Here is what prior authorizations do:
- they aim to drive cost down for insurance companies, and serves as few patients as possible
- they waste clinicians’ time for patient care
- they waste nursing staff’s time for patient care
- they hurt patients by dictating what happens in the exam rooms without actually being there

👏Prior 👏 Authorizations 👏 Are 👏SCAMS 👏 and 👏 they 👏 harm 👏 patients 👏

You know what I’m going to do? I’m going to get my patient the FUCKING medicine. 🤬

https://t.co/b0FXofLd90

[Christian Fernandez Olortegui @ChrisFernOlor]

@toddscarbrough Who is giving 26Gy boosts? 🤔

[Lea Alhilali, MD @teachplaygrub]

1/Can’t seem to strike the right CHORD when it comes to chordomas?

Do chordomas frighten you to the core?

What do you KNOW about the NOTOchord?

Never fear, here’s a thread to teach you what you NEED to know about the diagnosis & treatment of chordomas!

[Matthias Guckenberger @Mat_Guc]

First prospective data of SBRT for early stage NSCLC in pts with interstitial lung disease
👉 risk of treatment-related mortality 7.7%
👉 median OS 25mo
👍 prespecified acceptability thresholds for toxicity & efficacy met
👏 @drdavidpalma and colleagues
https://t.co/aaBsUwLecu

[JAMA Oncology @JAMAOnc]

Results of this randomized clinical trial suggest that after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma, radiotherapy alone was noninferior to chemoradiotherapy in terms of 3-year progression-free survival. https://t.co/RMI1OMHG5y

[STV News @STVNews]

No cervical cancer cases have been detected in women who have been fully vaccinated against HPV, Public Health Scotland has revealed.
https://t.co/FiWZMAw6jw

[Krishan Jethwa @KrishanJethwa]

🚨🚨🚨
Rectal Cancer Tweetorial!!

Rectal cancer is a highly heterogeneous disease with rapid evolution in practice.

Let's review current data to generate a pragmatic, patient-centric, approach to management!
#GI24 #GIonc #RadOnc

Thank you @ASCO for the opportunity!🙏🏽

1/

[Arndt Vogel @ArndtVogel]

Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer
@Annals_Oncology
https://t.co/NDiGvRMWvZ
👉1st randomised trial addressing the timing of surgery after nCRT
🧐Do not delay surgery >6 weeks, TRG 4 fared particularly badly
@myESMO

[PDBrown @PDBrownOnc]

Targeted geneexpression biomarker for Meningioma risk stratification
· Re-classified over 1/2meningiomas compared to conventional clinical criteria
· Predict which Gr2 benefit from RT
· https://t.co/WfnkAz1neW